1. Market Research

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US)

  • March 2015
  • Firstword Pharma
Report ID: 3509581

Summary

Table of Contents




FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5) provides cutting edge, advanced and proprietary analytics that companies operating in the MS space need to develop, shape and refine brand strategy.

Critically, the report quantifies the impact and influence of specific environmental barriers – such as price, availability and reimbursement – in relation to how much market share your brand gains and loses, to which brands your share is going to, and from which brands your brand is getting share from.

The proprietary barrier instrument utilizes statistical analysis and advanced calculation to provide you with this precise information. This information allows you to act strategically and focus on the market barriers that can drive market share gains and improve competitiveness for your brand.







Key Issues Expored

Each brand's current user base, plus doctors who are not current users but would consider using it
In the market, the percentage of prescriptions influenced by barriers, the barriers experienced and the volume of prescriptions these barriers represent
Amount of share each brand gains/loses due to the barriers

Get Answers to Critical Questions

What brands are US physicians prescribing to their MS patients?/BulletPoint>
What is the top market barrier that forces a physician to prescribe a drug they didn’t intend to?/BulletPoint>
Which MS drug gains the most and least share due to current market barriers?/BulletPoint>
Which MS drug is benefiting the most from current market barriers?/BulletPoint>
What are the most common barriers in the US that cause a brand to gain and lose market share?/BulletPoint>


MS Brands Reviewed

Avonex (interferon-beta-1a)
Rebif (interferon-beta-1a)
Betaseron (interferon-beta-1b)
Extavia (interferon-beta-1b)
Copaxone (glatiramer acetate; including daily and 3x weekly formulations)
Gilenya (fingolimod)
Tecfidera (dimethyl fumarate)
Aubagio (teriflunomide)
Tysabri (natalizumab)


Methodology


Sample Distribution
150 neurologists in the France, Italy, Spain, Germany and the UK.

Interviewing Methodology
Data collected via a 10-minute questionnaire.

Screening Criteria
See at least 2 relapsing/remitting MS patients in past month
Have been in active practice 2+ years
Prescribed at least one of the listed products

About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. FirstWord Reports provide expert views and intelligence on the challenges facing pharma today in these topic areas: Biosimilars, Market Access, Medical Affairs, Sales & Marketing, Technology, Therapy Areas.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

Learn more at www.firstwordgroup.com.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.